AGLE Aeglea BioTherapeutics Inc

Price (delayed)

$0.5821

Market cap

$29.35M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.09

Enterprise value

$17.81M

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product ...

Highlights
Aeglea BioTherapeutics's debt has decreased by 8% YoY and by 2.4% QoQ
The gross profit rose by 7% since the previous quarter
AGLE's EPS is up by 17% YoY but it is down by 9% QoQ
The net income has increased by 10% year-on-year but it has declined by 9% since the previous quarter
The company's equity has shrunk by 50% YoY and by 27% QoQ
Aeglea BioTherapeutics's quick ratio has decreased by 10% QoQ and by 8% YoY

Key stats

What are the main financial stats of AGLE
Market
Shares outstanding
50.42M
Market cap
$29.35M
Enterprise value
$17.81M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.47
Price to sales (P/S)
1.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.89
Earnings
Revenue
$20.1M
EBIT
-$71.88M
EBITDA
-$69.84M
Free cash flow
-$60.61M
Per share
EPS
-$1.09
Free cash flow per share
-$0.92
Book value per share
$1.25
Revenue per share
$0.3
TBVPS
$1.26
Balance sheet
Total assets
$83.17M
Total liabilities
$21.51M
Debt
$4.92M
Equity
$61.66M
Working capital
$56.3M
Liquidity
Debt to equity
0.08
Current ratio
4.45
Quick ratio
4.27
Net debt/EBITDA
0.17
Margins
EBITDA margin
-347.5%
Gross margin
100%
Net margin
-358.3%
Operating margin
-357.6%
Efficiency
Return on assets
-61.4%
Return on equity
-78.6%
Return on invested capital
-91.1%
Return on capital employed
-107.5%
Return on sales
-357.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGLE stock price

How has the Aeglea BioTherapeutics stock price performed over time
Intraday
-10.45%
1 week
-10.45%
1 month
-57.51%
1 year
-91.74%
YTD
-87.75%
QTD
-74.69%

Financial performance

How have Aeglea BioTherapeutics's revenue and profit performed over time
Revenue
$20.1M
Gross profit
$20.1M
Operating income
-$71.88M
Net income
-$72.02M
Gross margin
100%
Net margin
-358.3%
Aeglea BioTherapeutics's operating income has increased by 11% YoY but it has decreased by 9% QoQ
The net income has increased by 10% year-on-year but it has declined by 9% since the previous quarter
The gross profit rose by 7% since the previous quarter
AGLE's revenue is up by 7% QoQ

Growth

What is Aeglea BioTherapeutics's growth rate over time

Valuation

What is Aeglea BioTherapeutics stock price valuation
P/E
N/A
P/B
0.47
P/S
1.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.89
AGLE's EPS is up by 17% YoY but it is down by 9% QoQ
AGLE's P/B is 83% below its last 4 quarters average of 2.8 and 82% below its 5-year quarterly average of 2.6
The company's equity has shrunk by 50% YoY and by 27% QoQ
AGLE's price to sales (P/S) is 92% lower than its last 4 quarters average of 23.1
AGLE's revenue is up by 7% QoQ

Efficiency

How efficient is Aeglea BioTherapeutics business performance
The company's return on equity fell by 35% YoY and by 28% QoQ
Aeglea BioTherapeutics's ROA has decreased by 28% from the previous quarter and by 25% YoY
AGLE's return on invested capital is up by 15% year-on-year but it is down by 9% since the previous quarter
AGLE's ROS is down by 2.1% QoQ

Dividends

What is AGLE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGLE.

Financial health

How did Aeglea BioTherapeutics financials performed over time
Aeglea BioTherapeutics's total assets has decreased by 49% YoY and by 24% QoQ
The company's total liabilities fell by 46% YoY and by 17% QoQ
Aeglea BioTherapeutics's debt is 92% lower than its equity
AGLE's debt to equity has surged by 100% year-on-year and by 33% since the previous quarter
The company's equity has shrunk by 50% YoY and by 27% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.